Table 2.

Randomized trials evaluating intention-modulated radiation therapy for localized prostate cancer.

Study	Year	Patient’s Number	PCa Characteristics	Dose (Gy)	ADT	bRFS (Phoenix)		Toxicity
NCT02257827	2016	109 vs. 106	low (43.7%), intermediate (21.9%), and high (34.4%) risk	70 (IMRT) vs. 70 (3DCRT)	2 years in intermediate- and high-risk patients	5-year	95.4% vs. 94.3%	6-month grade ≥ 2 GU toxicity	3% vs. 4%	6-month grade ≥ 2 GI toxicity	1% vs. 9%
The PROFIT trial	2017	608 vs. 598	intermediate risk	60 (IMRT) vs. 78 (3DCRT)	only 6% of all patients	5-year	85% vs. 85%	6-month grade ≥ 3 GU toxicity	2.1% vs. 3.0%	grade ≥ 3 GI toxicity	1.5% vs. 2.7%
RTOG 0126	2018	748 vs. 751	low or intermediate risk	79.2 vs. 70.2	-	8-year	80% vs. 75%	5-year grade ≥ 2 GU toxicity	12% vs. 7%	5-year grade ≥ 2 GI toxicity	21% vs. 15%
POP-RT	2021	110 vs. 114	high risk	68 + 50 vs. 68	2 years	5 year	95.0% vs. 81.2%	late grade ≥ 2 GU toxicity	20.0% vs. 9.0%	late grade ≥ 2 GI toxicity	8.2% vs. 4.5%

PCa, prostate cancer; Gy, gray; ADT, androgen deprivation therapy; bRFS, biochemical relapse-free survival; IMRT, intensity modulated radiation therapy; 3DCRT, three-dimensional conformal radiation therapy; GU, genitourinary; GI, gastrointestinal.